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This Letter investigated the efficacy of a decision-support system, designed for respiratory medicine, at predicting asthma exacerbations in a
multi-site longitudinal randomised control trial. Adherence to inhaler medication was acquired over 3 months from patients with asthma
employing a dose counter and a remote monitoring adherence device which recorded participant’s inhaler use: n = 184 (23,656 audio
files), 61% women, age (mean ± sd) 49.3 ± 16.4. Data on occurrence of exacerbations was collected at three clinical visits, 1 month apart.
The relative risk of an asthma exacerbation for those with good and poor adherence was examined employing a univariate and
multivariate modified Poisson regression approach; adjusting for age, gender and body mass index. For all months dose counter adherence
was significantly (p < 0.01) higher than remote monitoring adherence. Overall, those with poor adherence had a 1.38 ± 0.34 and 1.42 ±
0.39 (remotely monitored) and 1.25 ± 0.32 and 1.18 ± 0.31 (dose counter) higher relative risk of an exacerbation in model 1 and model 2,
respectively. However, this was not found to be statistically significantly different. Remotely monitored adherence holds important clinical
information and future research should focus on refining adherence and exacerbation measures. Decision-support systems based on remote
monitoring may enhance patient–physician communication, possibly reducing preventable adverse events.
1. Introduction: Asthma is a common chronic disease globally
affecting 300 million people [1]. It is characterised by recurrent
attacks of breathlessness and wheezing that may vary in severity
and frequency between individuals. Asthma cannot be cured, but
appropriate management and adherence to medication can control
the disorder, reducing severity and adverse events and increasing
quality of life [2].
The biology of an asthma exacerbation is complex, involving
many factors. Behaviour, in particular adherence behaviour is a
key factor in ensuring the delivery of prescribed treatment.
Previous studies have found forming a habit of adherence to be fun-
damental [3]. Other factors such as personal characteristics and en-
vironmental factors also influence clinical outcomes. These
personal characteristics can be inherent, some are constant such
as gender and height, others stable such as age or have the ability
to be changed such as weight or body mass index (BMI).
Determining predictors of asthma exacerbations would be clinic-
ally beneficial to prevent or reduce the occurrence of adverse events
and to recognise the early signs of an asthma exacerbation. Previous
studies have examined predictors of respiratory exacerbations
employing conditional probability to examine links with peak ex-
piratory flow rate [4], multivariate logistic regression to examine
links with dyspnea scores [5] and exploring links between exacer-
bations and previous exacerbations [6], among others [7, 8]. Poor
or non-adherence to inhaled medication is thought to be a key
cause of exacerbations [9]. However, there is limited knowledge
on the efficacy of a medication adherence measure at identifying
risk of adverse events or as a predictor of asthma exacerbations
[10]. More objective measures of adherence are required also, and
recent studies have examined the benefit of remote monitoring [11].
This Letter aimed to examine the efficacy of a simple,
cost-effective remote monitoring tool at predicting asthma exacer-
bations. This monitoring tool was designed as a clinical decision-
support system. Further validating this tool as a screen for risk of
asthma exacerbations could aid preventative clinical strategies by
highlighting those patients at risk of adverse events and informing
physicians on efficacy of medication dosing.
2. Procedure: This Letter employed longitudinal data from 184
participants with asthma [61% women, age (mean ± sd) 49.3 ±
16.4] who participated in the inhaler compliance assessment
study (INCA-1) [12], a randomised, parallel-group, multi-centre
trial (NCT01529697) employing a novel remote monitoring
device (the INCA™ device) [13–17] to measure and monitor
compliance to Seretide Diskus™ dry powder inhaler (DPI).
The INCA device is a validated [13, 15] remote monitoring
device employed to assess inhaler compliance by audio recording
patients using their inhaler. The INCA device which consists of a
microphone, a solid-state memory storage, a microprocessor and a
battery for recording audio, is attached to an inhaler as shown in
Fig. 1 (top). Recording is initiated when the inhaler is opened
and ends on closing the inhaler as shown in Fig. 2 (bottom). An
electronic real-time clock time stamps the recording and this time
stamp is stored as part of the file’s metadata. A sampling rate of
8 kHz with an 8-bit sampling resolution is employed to record
the audio. During correct inhaler usage, this audio consists of a se-
quence of distinct features: medication blistering, exhalation away
from the inhaler, medication inhalation through the inhaler mouth-
piece and subsequent holding of breath as shown in Fig. 2. The
audio files are downloaded from the INCA™ device and processed
by file transfer protocol software for subsequent analysis of each
audio file by a previously validated algorithm [13–16]. Each
audio file is classified as (i) used correctly or (ii) used incorrectly
which is further classified according to the type of technique error
(exhale into mouthpiece, no blister, no inhalation, low inspiratory
flow rate, multiple inhalation, multiple blisters). The algorithm
outputs this information on inhaler adherence to the clinician
along with patient identification number and, date, time and dur-
ation of inhaler use. This facilitates inhaler use feedback to the
patient resulting in adherence education which may prevent
adverse events and improve clinical outcomes.
3. Methods: All assessments were performed in a clinical trial
centre by either a research nurse or a medical doctor specialising
in respiratory medicine. This clinical trial (INCA-1) was a
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multi-centre clinical trial involving five sites within the Republic of
Ireland. Assessments were performed over 3 months which
involved four separate visits 1 month apart, beginning with visit
1 and following with visit 2, visit 3 and visit 4. All sites received
full education and training on the study protocol [12] ensuring
standardisation of all procedures performed. All equipment
required was provided to each centre.
A case record form was designed to record all data captured.
Personal characteristics (age, gender, height and weight) were col-
lected from the INCA-1 monthly assessments. Adverse event data
was collected at all follow-up visits (visit 2, visit 3 and visit 4)
detailing a description of the event and its duration when partici-
pants were asked: ‘Have you experienced an adverse event since
your last visit?’. Subsequently, these descriptions were classified
into either respiratory or non-respiratory adverse events and
further into lower and upper respiratory tract adverse events by clin-
icians specialising in respiratory medicine. There is no clear
definition for an asthma exacerbation. However, it is commonly
defined as the need for treatment with systemic corticosteroids, wor-
sening asthma requiring hospital admission or emergency treat-
ment, or a decrease in morning peak flow >25% of baseline on
two consecutive days [18, 19]. This Letter has taken a conservative
approach and classified an exacerbation as a lower respiratory tract
adverse event of 3 days or more duration.
At visit 1, visit 2 and visit 3 all participants were dispensed a
Diskus™ inhaler with an INCA™ device attached. At all follow-up
visits (at visit 2, visit 3 and visit 4), the research nurse recorded the
medication dose counter number displayed on the inhaler and
uploaded device audio files for automatic adherence analysis.
Attempted doses were defined as all participant audio recordings
regardless of inhaler technique. Actual doses were defined as those
recordings which were classified as not having a technique error.
Technique errors were: low inspiratory flow rate, multiple inhala-
tions, multiple blisters, blister present no inhalation detected, no
blister detected inhalation present, no blister and no inhalation, mul-
tiple inhalations and multiple blisters, and exhaling into the
mouthpiece.
Remotely monitored adherence and dose counter adherence were
calculated as follows:
RemotelyMonitoredAdherence [%] = Actual Doses
ExpectedDoses
∗ (100)
DoseCounter Adherence [%] = DoseCounter Doses
ExpectedDoses
∗ (100)
Where:
Attempted Doses = Attempted Doses per visit per participant.
Actual Doses = Actual Doses per visit per participant
Expected Doses = Prescribed daily dose (2 doses a day) over dur-
ation of analysis
Dose Counter Doses = medication dose counter number.
Participants were classified into those who had an exacerbation
and those who had not, generating a binary exacerbation measure.
Remotely monitored adherence and dose counter adherence were
both categorised into those with good adherence (≥80%) and
those with poor adherence (<80%). Exacerbation, remotely moni-
tored adherence and dose counter adherence measures were calcu-
lated for each participant for the total length of the clinical trial (3
months) and for each month: month 1, month 2 and month 3.
Data was analysed using Stata 14 (StataCorp LP, Texas, USA). A
t-test (p < 0.05) was employed to examine differences in dose
counter adherence and remotely monitored adherence. A modified
Poisson regression (p < 0.05) was employed to estimate the effect
of adherence on exacerbation occurrence based on relative risk.
Poisson regression can overestimate relative risk, however this
can be rectified in a novel modified Poisson regression by employ-
ing a robust error variance procedure known as sandwich estimation
[20]. This modified Poisson regression has been validated in pro-
spective studies with subject numbers similar to those employed
in this Letter [21]. In this Letter, two modified Poisson regression
models (model 1 and model 2) were employed to compare the
odds ratio and the relative risk of exacerbation occurrence for
those with poor adherence against those with good adherence.
Model 1 employed a univariate modified Poisson regression.
Model 2 also adjusted for age, gender and BMI. Both models
were examined over the total duration of the clinical trial (3
months) and for each month (month 1, month 2 and month 3).
4. Results: Personal characteristics of the 184 participants included
in the analysis were: 61% female (n = 114), mean ± sd interquartile
range (IQR): age 49.3 ± 16.4 (37.1–63.1), BMI 29.3 ± 6.8 (24.9–
32.3). Number of respiratory adverse events, lower respiratory
tract adverse events and asthma exacerbations can be seen in
Table 1. The overall incidence rate of a respiratory adverse event
Fig. 2 Acoustic signals recorded from the INCA device showing correct
inhaler technique [14]
Fig. 1 INCA device attached to a DiskusTM DPI (top) [16]. Functional com-
ponents of the inhaler (bottom) [14]
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was found to be 31%. There were 23,656 audio files recorded for all
participants over 3 months.
It was found that dose counter adherence statistically significant-
ly differed from remotely monitored adherence (t-test p < 0.01) with
mean ± sd adherence 81.8 ± 52.4, 76.1 ± 42.7 and 74.0 ± 44.0% for
dose count adherence compared with 49.3 ± 50.1, 57.0 ± 49.6 and
56.0 ± 50.0% for remotely monitored adherence for month 1,
month 2 and month 3, respectively.
Results for statistical model 1 and model 2 can be found in
Table 2. In model 1, over the total duration of the clinical trial (3
months) the relative risk of having an asthma exacerbation was
1.38 ± 0.34 (0.82–2.20) (mean ± sd (IQR)) higher for those with
poor adherence employing the remotely monitored adherence,
and 1.25 ± 0.32 (0.77–2.06) higher employing dose counter adher-
ence, when compared with those with good adherence.
In model 1, when examining each month separately and employ-
ing remotely monitored adherence, those with poor adherence were
found to have a higher relative risk of having an asthma exacerba-
tion when compared with those with good adherence [1.13 ± 0.48
(month 1), 1.29 ± 0.48 (month 2) (mean ± sd)], with the exception
of month 3 (0.51 ± 0.29). Similarly, for dose counter adherence
those with poor adherence were found to have a higher risk of
asthma exacerbations when compared with those with good adher-
ence [1.22 ± 0.62 (month 1), month 3 (1.23 ± 0.46) (mean ± sd)],
with the exception of month 2 (0.83 ± 0.38). However, model 1
results were not found to be statistically significantly different.
In model 2, over the total duration of the clinical trial (3 months),
the relative risk of having an asthma exacerbation was 1.42 ± 0.39
(0.83–2.44) (mean ± sd (IQR)) higher for those with poor adherence
employing the remotely monitored adherence and, 1.18 ± 0.31
(0.71–1.96) higher employing dose counter adherence when com-
pared with those with good adherence.
In model 2, when examining each month separately and employ-
ing remotely monitored adherence, those with poor adherence were
found to have a higher relative risk of having an asthma exacerba-
tion when compared with those with good adherence [month 1
(1.74 ± 0.89), month 2 (1.25 ± 0.46) (mean ± sd)], with the excep-
tion of month 3 (0.41 ± 0.23). When employing dose counter adher-
ence those with poor adherence were found to have a higher risk of
asthma exacerbations when compared with those with good adher-
ence [month 1 (1.32 ± 0.66), month 3 (1.14 ± 0.42) (mean ± sd)],
with the exception of month 2 (0.65 ± 0.32). However, results for
model 2 were not found to be statistically significantly different.
Similar results were found when investigating the odds ratios of a
participant having an asthma exacerbation where an overall increase
in odds ratio was found for those with poor adherence compared
with those with good adherence, however this relationship was
less clear when examining the relationship between adherence
and exacerbation risk across each month as can be seen in Fig. 3
(for model 1 and model 2).
5. Discussion: The relative risk of asthma exacerbation occurrence
was investigated in a multi-site longitudinal randomised control
trial. The primary aim was to investigate the efficacy of
adherence acquired from a remote monitoring device at predicting
risk of asthma exacerbations compared with that from the
commonly employed dose counter. It was found that dose counter
adherence was significantly (p < 0.01) higher than remote
monitoring adherence during month 1, month 2 and month
3. Overall, across the total duration of the clinical trial (3 months)
those with poor adherence ( < 80%) were found to have a higher
relative risk and odds ratio of asthma exacerbation occurrence
(when compared with those with good adherence (≥80%)) if
measured by remote monitoring when compared with a dose
counter. However, overall both remotely monitored adherence
and dose counter adherence were found to predict asthma
exacerbations. The INCA device was designed as a
decision-support system for physicians and as a tool to improve
asthma inhaler adherence by aiding communication between
patient and healthcare professional. The results found in this
Letter indicate that this adherence data may additionally inform
clinicians on exacerbation risk, potentially reducing exacerbations
thereby improving quality of life.
Remotely monitored adherence (49.3 ± 50.1, 57.0 ± 49.6 and
56.0 ± 50.0% (mean ± sd)) was significantly (p < 0.01) lower than
dose counter adherence (81.8 ± 52.4, 76.1 ± 42.7 and 74.0 ±
44.0%) for month 1, month 2 and month 3, respectively. This
shows that the INCA remote monitoring device is acquiring import-
ant objective data by excluding incorrect inhaler use. This supports
the employment of remote monitoring devices which can acquire
relevant objective clinical information, in this instance a more
Table 1 Number of adverse events and exacerbations per month
Measure Month 1 Month 2 Month 3
adverse events (AEs) 36 38 40
lower respiratory AEs 28 29 31
asthma exacerbations 22 26 27
Table 2 Estimated relative risk of asthma exacerbations when comparing those with poor adherence to those with good adherence for the total 3-month
duration of the clinical trial (overall) and for month 1, month 2 and month 3: model 1 and model 2
All participants
Predictor Overall Month 1 Month 2 Month 3
Model 1
RR ± SE*
(range)
(p-value)
Model 2
RR ± SE*
(range)
(p-value)
Model 1
RR ± SE*
(range)
(p-value)
Model 2
RR ± SE*
(range)
(p-value)
Model 1
RR ± SE*
(range)
(p-value)
Model 2
RR ± SE*
(range)
(p-value)
Model 1
RR ± SE*
(range)
(p-value)
Model 2
RR ± SE*
(range)
(p-value)
dose counter adherence 1.25 ± 0.32
(0.77–2.06)
0.366
1.18 ± 0.31
(0.71–1.96)
0.531
1.22 ± 0.62
(0.45–3.31)
0.693
1.32 ± 0.66
(0.49–3.51)
0.582
0.83 ± 0.38
(0.34–2.04)
0.684
0.65 ± 0.32
(0.24–1.71)
0.379
1.23 ± 0.46
(0.59–2.56)
0.585
1.14 ± 0.42
(0.55–2.33)
0.73
remotely monitored adherence 1.38 ± 0.34
(0.82–2.20)
0.251
1.42 ± 0.39
(0.83–2.44)
0.199
1.13 ± 0.48
(0.49–2.6)
0.768
1.74 ± 0.89
(0.64–4.73)
0.274
1.29 ± 0.48
(0.63–2.65)
0.493
1.25 ± 0.46
(0.61–2.56)
0.548
0.51 ± 0.29
(0.17–1.6)
0.241
0.41 ± 0.23
(0.13–1.24)
0.113
*Statistical model 1: the estimated relative risk and standard error for the dose counter and remotely monitored adherence, respectively, based on univariate analysis:
n = 128, 156, 148 and 137 for overall, month 1, month 2 and month 3, respectively. Statistical model 2: the estimated relative risk for the dose counter and remotely
monitored adherence, respectively, adjusting for age, gender and BMI: n = 118, 140, 135 and 126 for overall, month 1, month 2 and month 3, respectively.
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accurate description of the amount of medication delivered to the
patient.
For both adherence measures, those participants with poor
inhaler adherence over the total duration of the clinical trial (3
months) had a higher relative risk of exacerbation incidence in
model 1 and in model 2 after adjusting for confounding factors
(age, gender and BMI) when compared with those with good adher-
ence. This relative risk was higher employing remotely monitored
adherence (1.38 ± 0.34, 1.42 ± 0.39 (mean ± sd)) compared with
dose counter adherence (1.25 ± 0.32, 1.18 ± 0.31) for model 1 and
model 2, respectively.
Results were varied when examining the relationship between
adherence and exacerbation occurrence each month. In the fully
adjusted model those with poor adherence had a 1.74 ± 0.89,
1.25 ± 0.46 and 0.41 ± 0.23 (remotely monitored) (mean ± sd) and
1.13 ± 0.48, 1.29 ± 0.48 and 0.51 ± 0.29 (dose counter) relative
risk of an exacerbation in month 1, month 2 and month 3, respect-
ively, when compared with those with good adherence. However,
these differences were not found to be statistically significantly dif-
ferent. Similar results were found for model 1 with a minor effect of
covariates (age, gender and BMI) as can be seen in Table 2 and
Fig. 3. This suggests that the adherence measures employed here
are not sufficiently sensitive over this shorter monitoring time (1
month). However, employing a more descriptive adherence
measure, in addition to a less conservative definition of exacerba-
tion may yield better results.
The effect of covariates can be seen in the reduced relative risk in
Table 2 and odds ratio in Fig. 3 from statistical model 1 to model
2. This shows the importance of adjusting for confounding
factors to aid in highlighting variables of most interest. However,
other covariates such as smoking status, baseline lung function in
addition to know triggers of asthma exacerbations which may
hold important clinical information (pollution, season and
viruses), may be beneficial to include also. This Letter employed
a modified Poisson regression to calculate relative risk of asthma
exacerbations. This method is supported by previous literature
[22, 23] and has been found to be relatively robust to omitted cov-
ariates [21].
The results from this Letter indicate that remotely monitored ad-
herence holds important clinical information. Future research
should focus on building a more robust adherence measure which
may include duration between administering medication, in add-
ition to cumulative effect of missed doses. We hypothesise that in-
clusion of such additional elements of adherence would increase the
predictive power of remotely monitored adherence.
This Letter examined the efficacy of a design support system at
predicting risk of asthma exacerbations. Overall, the remotely mon-
itored adherence measure calculated by this system was found to
predict asthma exacerbations over a 3-month clinical trial. In add-
ition, the adherence values calculated were found to be statistically
significantly lower than those calculated from a commonly
employed dose counter. Over shorter monitoring durations
(1 month) the predictive value was unclear. In conclusion, remotely
monitored poor adherence (<80%) holds important clinical infor-
mation as it showed some predictive value for future exacerbations.
Further refinement of this system may allow a clinically useful pre-
ventative tool be developed which may highlight those patients at
risk of adverse events and inform physicians on efficacy of medica-
tion dosing. Decision-support systems based on remote monitoring
may enhance patient–physician communication to aid clinical out-
comes and quality of life, in addition to reducing preventable
adverse events.
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